In recent years, immune checkpoint inhibitors with CTLA-4, PD-1 and PD-L1 monoclonal antibodies has become a successful treatment for several advanced cancers (Wojtukiewicz et al., 2021). This evidence concerns the gene PDCD1 and cancer.